A Study of BMS-986249 Alone and in Combination With Nivolumab in Advanced Solid Tumors

No strong warning signs right now. The score counts warning signs; it is not a prediction.

Why this score

Score over time

What counts as success

The trial's main goal(s), called the “primary outcome.”

• Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs) - Part 1 A and 1 B

  Measured over: From first dose until 100 days after last dose of study therapy (up to approximately 38 weeks)

• Number of Participants With Adverse Events (AEs) Meeting Protocol-Defined Dose-Limiting Toxicity (DLT) Criteria - Part 1 A and 1 B

  Measured over: From first dose until 5 weeks after first dose of study medicine (up to approximately 5 weeks)

• Number of Participants Who Died - Part 1 A and 1 B

  Measured over: From enrollment until the date of death from any cause (up to approximately 83 months)

• Number of Participants With Shifts From Baseline in Laboratory Tests Results - Part 1 A and 1 B

  Measured over: From first dose until 100 days after last dose of study therapy (up to approximately 38 weeks)

• Number of Participants With Treatment-Related Grade 3-5 Adverse Events (AEs) Within 24 Weeks - Part 2 A Arms C, D and F, and Part 2 B

  Measured over: From first dose until 24 weeks after first dose (up to approximately 24 weeks)

• Objective Response Rate (ORR) as Assessed by Investigator - Part 2 A Arm C and F

  Measured over: From randomization until progression or death from any cause (up to approximately 83 months)

Changes Tremor has spotted